Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies

[1]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[2]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[3]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[4]  Jung Hun Song,et al.  An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. , 2006, The Journal of clinical endocrinology and metabolism.

[5]  Andrea Sbarbati,et al.  Early Antiangiogenic Activity of SU11248 Evaluated In vivo by Dynamic Contrast-Enhanced Magnetic Resonance Imaging in an Experimental Model of Colon Carcinoma , 2005, Clinical Cancer Research.

[6]  R. Herbst,et al.  Current management of advanced non-small cell lung cancer: targeted therapy. , 2005, Seminars in oncology.

[7]  M. Stamos,et al.  Strategies for Palliative Care in Advanced Colorectal Cancer , 2005, Digestive Surgery.

[8]  R. Warren,et al.  Palliative techniques for hepatic cancer. , 2004, Surgical oncology clinics of North America.

[9]  J. Doroshow,et al.  SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  J. Yap,et al.  Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Kwiatkowski.  Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis , 2003, Cancer biology & therapy.

[12]  N. Pryer,et al.  SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. , 2003, Molecular cancer therapeutics.

[13]  M. Heinrich,et al.  SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. , 2003, Blood.

[14]  Joel S. Karp,et al.  Implementation of a single scatter simulation algorithm for 3D PET: application to emission and transmission scanning , 2002, 2002 IEEE Nuclear Science Symposium Conference Record.

[15]  Robert B Livingston,et al.  Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  A. Scott.  Current status of positron emission tomography in oncology , 2001, Internal medicine journal.

[17]  H. Taniguchi,et al.  Correlation between angiographically assessed vascularity and blood flow in hepatic metastases in patients with colorectal carcinoma , 2000, Cancer.

[18]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[19]  Claude Comtat,et al.  Preserving Poisson characteristics of PET data with weighted OSEM reconstruction , 1998, 1998 IEEE Nuclear Science Symposium Conference Record. 1998 IEEE Nuclear Science Symposium and Medical Imaging Conference (Cat. No.98CH36255).

[20]  A A Lammertsma,et al.  Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. , 1992, Cancer research.

[21]  Paul Kinahan,et al.  Analytic 3D image reconstruction using all detected events , 1989 .

[22]  H. Hollema,et al.  VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. , 2011, Cancer research.

[23]  M. Edelman,et al.  Management of common symptoms of advanced lung cancer , 2005, Current treatment options in oncology.

[24]  N. Pryer,et al.  SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model , 2004, Clinical & Experimental Metastasis.

[25]  Juthamas Sukbuntherng,et al.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.